These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8642858

  • 1. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia.
    Campos L, Sabido O, Sebban C, Charrin C, Bertheas MF, Fière D, Guyotat D.
    Leukemia; 1996 Mar; 10(3):434-8. PubMed ID: 8642858
    [Abstract] [Full Text] [Related]

  • 2. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line.
    Kiem HP, Nourse J, Saltman DL, Blume KG, Cleary ML.
    Oncogene; 1990 Dec; 5(12):1815-9. PubMed ID: 2284100
    [Abstract] [Full Text] [Related]

  • 3. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R.
    Clin Cancer Res; 2005 Apr 15; 11(8):2974-80. PubMed ID: 15837750
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia.
    Schaich M, Illmer T, Seitz G, Mohr B, Schäkel U, Beck JF, Ehninger G.
    Haematologica; 2001 May 15; 86(5):470-7. PubMed ID: 11410409
    [Abstract] [Full Text] [Related]

  • 5. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
    Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR.
    Leukemia; 1994 Dec 15; 8(12):2118-26. PubMed ID: 7807999
    [Abstract] [Full Text] [Related]

  • 6. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
    Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Aricò M, Campana D.
    Blood; 1996 Feb 01; 87(3):1140-6. PubMed ID: 8562940
    [Abstract] [Full Text] [Related]

  • 7. Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study.
    Klobusická M, Kusenda J, Babusíkova O.
    Neoplasma; 2001 Feb 01; 48(6):489-95. PubMed ID: 11949843
    [Abstract] [Full Text] [Related]

  • 8. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor.
    Bradbury D, Zhu YM, Russell N.
    Leukemia; 1994 May 01; 8(5):786-91. PubMed ID: 8182935
    [Abstract] [Full Text] [Related]

  • 9. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
    Molica S, Mannella A, Dattilo A, Levato D, Iuliano F, Peta A, Consarino C, Magro S.
    Haematologica; 1996 May 01; 81(4):302-9. PubMed ID: 8870373
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
    Daneshbod Y, Amirghofran Z, Tabei SZ.
    Neoplasma; 2005 May 01; 52(2):109-14. PubMed ID: 15800708
    [Abstract] [Full Text] [Related]

  • 11. Myeloid surface antigen expression in adult acute lymphoblastic leukemia.
    Guyotat D, Campos L, Shi ZH, Charrin C, Treille D, Magaud JP, Fiere D.
    Leukemia; 1990 Sep 01; 4(9):664-6. PubMed ID: 1697640
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
    Zhou M, Gu L, Yeager AM, Findley HW.
    Leukemia; 1998 Nov 01; 12(11):1756-63. PubMed ID: 9823951
    [Abstract] [Full Text] [Related]

  • 13. bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation.
    Gratiot-Deans J, Ding L, Turka LA, Nuñez G.
    J Immunol; 1993 Jul 01; 151(1):83-91. PubMed ID: 8326141
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
    Konantz M, André MC, Ebinger M, Grauer M, Wang H, Grzywna S, Rothfuss OC, Lehle S, Kustikova OS, Salih HR, Handgretinger R, Fend F, Baum C, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K, Essmann F, Lengerke C.
    Leukemia; 2013 Jan 01; 27(1):56-65. PubMed ID: 22828445
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lack of c-kit proto-oncogene rearrangement in patients with acute lymphoblastic leukemia (ALL) and the t(4;11)(q21;q23) translocation.
    Schardt C, Stadler M, Hoelzer D, Ganser A.
    Leukemia; 1992 Oct 01; 6(10):1079-80. PubMed ID: 1383648
    [No Abstract] [Full Text] [Related]

  • 20. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X, Archimbaud E, Charrin C, Magaud JP, Fiere D.
    Leukemia; 1995 Feb 01; 9(2):249-53. PubMed ID: 7532767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.